Pathophysiology and management of liver cirrhosis: from portal hypertension to acute-on-chronic liver failure
暂无分享,去创建一个
M. Premkumar | A. Kulkarni | Mithun Sharma | P. Rao | Akash Roy | R. Jagdish | D. N. Reddy | Karan Kumar
[1] A. Mancuso,et al. Human Albumin Infusion for the Management of Liver Cirrhosis and Its Complications: An Overview of Major Findings from Meta-analyses , 2023, Advances in Therapy.
[2] D. Nageshwar Reddy,et al. Midodrine versus Albumin to Prevent Paracentesis Induced Circulatory Dysfunction in Acute on Chronic Liver Failure Patients in the Outpatient Clinic-a Randomized Controlled Trial. , 2023, Journal of clinical and experimental hepatology.
[3] H. Vargas,et al. Early treatment with terlipressin in patients with hepatorenal syndrome yields improved clinical outcomes in North American studies , 2023, Hepatology communications.
[4] A. Saraya,et al. Identification of risk factors associated with bacterial infections in Child-A cirrhosis with variceal bleeding , 2023, Journal of Clinical and Experimental Hepatology.
[5] Y. Wong,et al. Antibiotic prophylaxis in cirrhosis patients with upper gastrointestinal bleeding: An updated systematic review and meta‐analysis , 2022, Portal Hypertension & Cirrhosis.
[6] J. Trebicka,et al. MELD-Lactate Predicts Poor Outcome in Variceal Bleeding in Cirrhosis , 2022, Digestive Diseases and Sciences.
[7] A. Kulkarni,et al. SARS-CoV-2 Omicron variant infection was associated with higher morbidity in patients with cirrhosis , 2022, Gut.
[8] Brian C. Davis,et al. A double-blind randomized placebo-controlled trial of albumin in patients with hepatic encephalopathy: HEAL study. , 2022, Journal of hepatology.
[9] K. Reddy,et al. Terlipressin use and respiratory failure in patients with hepatorenal syndrome type 1 and severe acute‐on‐chronic liver failure , 2022, Alimentary pharmacology & therapeutics.
[10] R. Dhiman,et al. Assessment of Sarcopenia Using Muscle Ultrasound in Patients With Cirrhosis and Sarcopenic Obesity (AMUSE STUDY). , 2022, Journal of clinical gastroenterology.
[11] Y. Chawla,et al. Acute variceal bleeding portends poor outcomes in patients with acute-on-chronic liver failure: a propensity score matched study from the APASL ACLF Research Consortium (AARC) , 2022, Hepatology International.
[12] S. Sarin,et al. APASL‐ACLF Research Consortium–Artificial Intelligence (AARC‐AI) model precisely predicts outcomes in acute‐on‐chronic liver failure patients , 2022, Liver international : official journal of the International Association for the Study of the Liver.
[13] J. Schattenberg,et al. Frailty as Tested by the Clinical Frailty Scale Is a Risk Factor for Hepatorenal Syndrome in Patients With Liver Cirrhosis , 2022, Clinical and translational gastroenterology.
[14] A. Kulkarni,et al. Post-COVID-19 Cholestasis: A Case Series and Review of Literature , 2022, Journal of Clinical and Experimental Hepatology.
[15] J. Bedlington,et al. Palliative long-term abdominal drains for the management of refractory ascites due to cirrhosis: a consensus document , 2022, Frontline Gastroenterology.
[16] N. Reddy,et al. EARLY DIAGNOSIS AND PREVENTION OF INFECTIONS IN CIRRHOSIS. , 2022, Seminars in liver disease.
[17] M. Premkumar,et al. The challenges of ascites management: An Indian perspective , 2022, Clinical liver disease.
[18] N. Reddy,et al. Nonselective beta‐blockers reduce mortality in patients with acute‐on‐chronic liver failure , 2022, Portal Hypertension & Cirrhosis.
[19] S. Sarin,et al. Epidemiology of liver failure in Asia‐Pacific region , 2022, Liver international : official journal of the International Association for the Study of the Liver.
[20] P. Cortesi,et al. Location and allocation: Inequity of access to liver transplantation for patients with severe acute‐on‐chronic liver failure in Europe , 2022, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[21] Karan Kumar,et al. Response to Mir et al. , 2022, The American journal of gastroenterology.
[22] M. Premkumar,et al. Safety and efficacy of terlipressin in acute-on-chronic liver failure with hepatorenal syndrome-acute kidney injury (HRS-AKI): a prospective cohort study , 2022, Scientific Reports.
[23] D. Fan,et al. Concurrent large spontaneous portosystemic shunt embolization for the prevention of overt hepatic encephalopathy after TIPS: A randomized controlled trial , 2022, Hepatology.
[24] R. Schwabe,et al. Effect of rifaximin on infections, acute‐on‐chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFA‐AH) , 2022, Liver international : official journal of the International Association for the Study of the Liver.
[25] M. Premkumar,et al. Primary Norfloxacin Prophylaxis for APASL-Defined Acute-on-Chronic Liver Failure: A Placebo-Controlled Double-Blind Randomized Trial , 2022, The American journal of gastroenterology.
[26] P. Kamath,et al. Acute-on-Chronic Liver Failure Clinical Guidelines , 2022, The American journal of gastroenterology.
[27] N. Mahmud,et al. Statin exposure is associated with reduced development of acute on chronic liver failure in a veterans affairs cohort. , 2022, Journal of hepatology.
[28] H. Yoshiji,et al. Baveno VII - Renewing consensus in portal hypertension. , 2021, Journal of hepatology.
[29] B. Sharma,et al. L‐ornithine L‐aspartate in acute treatment of severe hepatic encephalopathy: A double‐blind randomized controlled trial , 2021, Hepatology.
[30] P. Ranjan,et al. A Prospective Study of Prevalence and Predictors of Cirrhotic Cardiomyopathy and Its Role in Development of Hepatorenal Syndrome. , 2021, Journal of clinical and experimental hepatology.
[31] A. Barritt,et al. SARS‐CoV‐2 Infections Among Patients With Liver Disease and Liver Transplantation Who Received COVID‐19 Vaccination , 2021, Hepatology communications.
[32] G. Saracco,et al. Transjugular intrahepatic porto-systemic shunt in cirrhotic patients with hepatorenal syndrome - chronic kidney disease: Impact on renal function. , 2021, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[33] M. Kumar,et al. ‘First week’ is the crucial period for deciding living donor liver transplantation in patients with acute-on-chronic liver failure , 2021, Hepatology International.
[34] A. Duseja,et al. Tuberculosis in Cirrhosis - A Diagnostic and Management Conundrum. , 2021, Journal of clinical and experimental hepatology.
[35] F. Saliba,et al. Sarcopenia should be evaluated in patients with acute-on-chronic liver failure and candidates to liver transplantation. , 2021, Journal of hepatology.
[36] A. Davenport,et al. P077 Pathophysiological basis of resolution of acute-on-chronic liver failure (ACLF) induced by the novel liver dialysis device, DIALIVE (ALIVER consortium) , 2021, Posters.
[37] N. Reddy,et al. COVID-19 Masquerading as Autoimmune Hepatitis (AIH) Flare—The First Report , 2021, Journal of Clinical and Experimental Hepatology.
[38] A. Davenport,et al. P076 A multi-centre, randomized controlled study, to evaluate the safety and performance of the DIALIVE liver dialysis device in patients with acute on chronic liver failure (ACLF) versus standard of care (SOC) (ALIVER Consortium) , 2021, Posters.
[39] P. Bachellier,et al. Pretransplant Intensive Care Unit Management and Selection of Grade 3 Acute‐on‐Chronic Liver Failure Transplant Candidates , 2021, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[40] H. Kaur,et al. Diagnosis and Management of Cirrhotic Cardiomyopathy. , 2021, Journal of clinical and experimental hepatology.
[41] S. Sarin,et al. Primary prophylaxis of gastric variceal bleeding: the choices need to be tested!! , 2021, Hepatology International.
[42] W. Kim,et al. Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases , 2021 .
[43] J. Lai,et al. Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases , 2021, Hepatology.
[44] S. Varughese,et al. Low Volume Plasma Exchange and Low Dose Steroid Improve Survival in Patients With Alcohol-Related Acute on Chronic Liver Failure and Severe Alcoholic Hepatitis - Preliminary Experience. , 2021, Journal of clinical and experimental hepatology.
[45] M. Trauner,et al. Decreasing von Willebrand Factor Levels Upon Nonselective Beta Blocker Therapy Indicate a Decreased Risk of Further Decompensation, Acute-on-chronic Liver Failure, and Death , 2021, Clinical Gastroenterology and Hepatology.
[46] S. Friedman,et al. Extensive Health Care Utilization and Costs of an Early Liver Transplantation Program for Alcoholic Hepatitis , 2021, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[47] Z. Duan,et al. Use of skeletal muscle index as a predictor of short-term mortality in patients with acute-on-chronic liver failure , 2021, Scientific Reports.
[48] Pramod Kumar,et al. Letter to the Editor: Living Donor Liver Transplantation or Deceased Donor Liver Transplantation in High Model for End‐Stage Liver Disease Score—Which Is Better? , 2021 .
[49] L. Laine,et al. Fresh frozen plasma transfusion in acute variceal haemorrhage: Results from a multicentre cohort study , 2021, Liver international : official journal of the International Association for the Study of the Liver.
[50] M. Chopra,et al. Fecal Microbiota Transplantation in Alcohol-Associated Acute on Chronic Liver Failure: An Open-label Clinical Trial , 2021 .
[51] C. Strassburg,et al. Elective Surgery but not Transjugular Intrahepatic Portosystemic Shunt Precipitates Acute‐On‐Chronic Liver Failure , 2021, Hepatology communications.
[52] Pramod Kumar,et al. Efficacy and safety of obeticholic acid in liver disease-A systematic review and meta-analysis. , 2021, Clinics and research in hepatology and gastroenterology.
[53] J. H. Kim,et al. Primary prophylaxis of gastric variceal bleeding: endoscopic obturation, radiologic intervention, or observation? , 2021, Hepatology International.
[54] S. Sarin,et al. Therapeutic plasma‐exchange improves systemic inflammation and survival in acute‐on‐chronic liver failure: A propensity‐score matched study from AARC , 2021, Liver international : official journal of the International Association for the Study of the Liver.
[55] C. Hamerski,et al. Safety and efficacy of EUS-guided coil and glue injection for the primary prophylaxis of gastric variceal hemorrhage. , 2021, Gastrointestinal endoscopy.
[56] S. Sarin,et al. Omega‐3 fatty acid lipid emulsions are safe and effective in reducing endotoxemia and sepsis in acute‐on‐chronic liver failure: An open‐label randomized controlled trial , 2021, Journal of gastroenterology and hepatology.
[57] Pramod Kumar,et al. Severe Acute Respiratory Syndrome Coronavirus 2–related Acute-on-chronic Liver Failure , 2020, Journal of Clinical and Experimental Hepatology.
[58] Pramod Kumar,et al. Midodrine Improves the Tolerability of Diuretics in Patients with Acute-on-Chronic Liver Failure-A Pilot Study. , 2020, Journal of clinical and experimental hepatology.
[59] S. Wong,et al. Timing of endoscopy for acute upper gastrointestinal bleeding: a territory-wide cohort study , 2020, Gut.
[60] Douglas A. Simonetto,et al. Terlipressin has stood the test of time: Clinical overview in 2020 and future perspectives , 2020, Liver international : official journal of the International Association for the Study of the Liver.
[61] R. Dhiman,et al. Combined PEG3350 Plus Lactulose Results in Early Resolution of Hepatic Encephalopathy and Improved 28-Day Survival in Acute-on-Chronic Liver Failure , 2020, Journal of clinical gastroenterology.
[62] Pramod Kumar,et al. Letter to the Editor: Midodrine for Hepatic Hydrothorax , 2020, Hepatology.
[63] A. Kulkarni,et al. Letter to the Editor: Sodium‐Glucose Cotransporter‐2 Inhibitors Are Not the Magic Pills for Control of Ascites in Cirrhosis and Diabetes , 2020, Hepatology.
[64] A. Singal,et al. Systematic review with meta‐analysis: liver transplant provides survival benefit in patients with acute on chronic liver failure , 2020, Alimentary pharmacology & therapeutics.
[65] Siddharth Singh,et al. Prevention of paracentesis‐induced circulatory dysfunction—A systematic review and network meta‐analysis , 2020 .
[66] Karan Kumar,et al. Prevention of paracentesis‐induced circulatory dysfunction‐ a systematic review and network meta‐analysis , 2020 .
[67] G. Garcia‐Tsao,et al. Sodium‐Glucose Cotransporter 2 Inhibitors Ameliorate Ascites and Peripheral Edema in Patients With Cirrhosis and Diabetes , 2020, Hepatology.
[68] R. Dhiman,et al. Important Unresolved Questions in the Management of Hepatic Encephalopathy: An ISHEN Consensus. , 2020, The American journal of gastroenterology.
[69] R. Talukdar,et al. Pathophysiology and Prevention of Paracentesis-induced Circulatory Dysfunction: A Concise Review , 2020, Journal of clinical and translational hepatology.
[70] N. Heaton,et al. Liver transplantation for critically ill cirrhotic patients: Stratifying utility based on pretransplant factors , 2020, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[71] S. Sarin,et al. Incidence, Risk Factors, and Outcomes of Transition of Acute Kidney Injury to Chronic Kidney Disease in Cirrhosis: A Prospective Cohort Study , 2020, Hepatology.
[72] A. Cohen-Solal,et al. Impact of cardiac function, refractory ascites and beta blockers on the outcome of patients with cirrhosis listed for liver transplantation. , 2020, Journal of hepatology.
[73] P. Charilaou,et al. Inpatient Mortality Benefit with Transjugular Intrahepatic Portosystemic Shunt for Hospitalized Hepatorenal Syndrome Patients , 2020, Digestive Diseases and Sciences.
[74] S. Sarin,et al. Intractable hepatic encephalopathy in cirrhotic patients: mid-term efficacy of balloon-occluded retrograde portosystemic shunt obliteration , 2020, European Radiology.
[75] R. Asokkumar,et al. Efficacy and safety of endoscopic ultrasound-guided therapy versus direct endoscopic glue injection therapy for gastric varices: systematic review and meta-analysis , 2020, Endoscopy.
[76] R. Jalan,et al. Recombinant Alkaline Phosphatase Prevents Acute on Chronic Liver Failure , 2020, Scientific Reports.
[77] N. Reddy,et al. Terlipressin-induced ischaemic skin necrosis , 2020, BMJ Case Reports.
[78] B. Colsch,et al. Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF. , 2019, Journal of hepatology.
[79] C. Strassburg,et al. The Development and Outcome of Acute‐on‐Chronic Liver Failure After Surgical Interventions , 2019, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[80] G. Garcia‐Tsao,et al. Portal Hypertension: Pathogenesis and Diagnosis. , 2019, Clinics in liver disease.
[81] A. Psyrri,et al. Tolvaptan Response Improves Overall Survival in Patients with Refractory Ascites: A Meta-Analysis , 2019, Digestive Diseases.
[82] P. Angeli,et al. News in Pathophysiology, Definition and Classification of Hepatorenal Syndrome: a step beyond the International Club of Ascites (ICA) Consensus document. , 2019, Journal of hepatology.
[83] S. Sarin,et al. Treatment with carvedilol improves survival of patients with acute-on-chronic liver failure: a randomized controlled trial , 2019, Hepatology International.
[84] D. Fan,et al. Early TIPS with covered stents versus standard treatment for acute variceal bleeding in patients with advanced cirrhosis: a randomised controlled trial. , 2019, The lancet. Gastroenterology & hepatology.
[85] M. Kumar,et al. Flare of Autoimmune Hepatitis Causing Acute on Chronic Liver Failure: Diagnosis and Response to Corticosteroid Therapy , 2019, Hepatology.
[86] S. Verma,et al. Permanent indwelling peritoneal catheters for palliation of refractory ascites in end‐stage liver disease: A systematic review , 2019, Liver international : official journal of the International Association for the Study of the Liver.
[87] S. Sarin,et al. Carvedilol Combined With Ivabradine Improves Left Ventricular Diastolic Dysfunction, Clinical Progression, and Survival in Cirrhosis , 2019, Journal of clinical gastroenterology.
[88] S. Caldwell,et al. AGA Clinical Practice Update: Coagulation in Cirrhosis. , 2019, Gastroenterology.
[89] Douglas A. Simonetto,et al. Management of Sepsis in Patients With Cirrhosis: Current Evidence and Practical Approach , 2019, Hepatology.
[90] Y. Chawla,et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update , 2019, Hepatology International.
[91] Y. Chawla,et al. Drug-Induced Acute-on-Chronic Liver Failure in Asian Patients. , 2019, The American journal of gastroenterology.
[92] N. Mahmud,et al. Incidence and Mortality of Acute‐on‐Chronic Liver Failure Using Two Definitions in Patients with Compensated Cirrhosis , 2019, Hepatology.
[93] M. Álvarez-Mon,et al. Dysfunctional Immune Response in Acute-on-Chronic Liver Failure: It Takes Two to Tango , 2019, Front. Immunol..
[94] K. Reddy,et al. Impact of Chronic Kidney Disease on Outcomes in Cirrhosis , 2019, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[95] M. Poca,et al. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial , 2019, The Lancet.
[96] C. Strassburg,et al. Sarcopenia Is Associated With Development of Acute-on-Chronic Liver Failure in Decompensated Liver Cirrhosis Receiving Transjugular Intrahepatic Portosystemic Shunt , 2019, Clinical and translational gastroenterology.
[97] Pengfei Guo,et al. A meta-analysis of randomized controlled trials , 2019, Medicine.
[98] J. Narciso-Schiavon,et al. Applicability of Sepsis‐3 criteria and quick Sequential Organ Failure Assessment in patients with cirrhosis hospitalised for bacterial infections , 2018, Liver international : official journal of the International Association for the Study of the Liver.
[99] P. Suñé,et al. Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial. , 2018, Journal of hepatology.
[100] P. Angeli,et al. Long‐term administration of human albumin improves survival in patients with cirrhosis and refractory ascites , 2018, Liver international : official journal of the International Association for the Study of the Liver.
[101] D. Gilroy,et al. ATTIRE: Albumin To prevenT Infection in chronic liveR failurE: study protocol for an interventional randomised controlled trial , 2018, BMJ Open.
[102] M. Norenberg,et al. Hyperammonemia in Hepatic Encephalopathy. , 2018, Journal of clinical and experimental hepatology.
[103] J. Trebicka,et al. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. , 2018, Journal of hepatology.
[104] Jong Seong Roh,et al. Damage-Associated Molecular Patterns in Inflammatory Diseases , 2018, Immune network.
[105] H. Büller,et al. Concepts and Controversies in Haemostasis and Thrombosis Associated with Liver Disease: Proceedings of the 7th International Coagulation in Liver Disease Conference , 2018, Thrombosis and Haemostasis.
[106] M. Rudler,et al. Preemptive‐TIPS Improves Outcome in High‐Risk Variceal Bleeding: An Observational Study , 2018, Hepatology.
[107] S. Caldwell,et al. Coagulation in Cirrhosis , 2018, Sherlock's Diseases of the Liver and Biliary System.
[108] A. Gasbarrini,et al. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial , 2018, The Lancet.
[109] G. Garcia‐Tsao,et al. Cardiopulmonary hemodynamics and C-reactive protein as prognostic indicators in compensated and decompensated cirrhosis. , 2018, Journal of hepatology.
[110] F. Bendtsen,et al. The pathophysiology of arterial vasodilatation and hyperdynamic circulation in cirrhosis , 2018, Liver international : official journal of the International Association for the Study of the Liver.
[111] B. Sharma,et al. L‐ornithine L‐aspartate in bouts of overt hepatic encephalopathy , 2018, Hepatology.
[112] S. Taylor-Robinson,et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial , 2017, Hepatology.
[113] Hui-Chun Huang,et al. The beneficial effects of curcumin in cirrhotic rats with portal hypertension , 2017, Bioscience reports.
[114] T. Berg,et al. Potentially inappropriate liver transplantation in the era of the "sickest first" policy - A search for the upper limits. , 2017, Journal of hepatology.
[115] M. Delgado-Rodríguez,et al. Systematic review and meta-analysis. , 2017, Medicina intensiva.
[116] L. DeLeve,et al. Liver Sinusoidal Endothelial Cell: An Update , 2017, Seminars in Liver Disease.
[117] S. Jaber,et al. Liver transplantation in the most severely ill cirrhotic patients: A multicenter study in acute-on-chronic liver failure grade 3. , 2017, Journal of hepatology.
[118] A. Frigo,et al. Assessment of Sepsis-3 criteria and quick SOFA in patients with cirrhosis and bacterial infections , 2017, Gut.
[119] J. Guzmán-De-Villoria,et al. Refractory hepatic encephalopathy in a patient with hypothyroidism: Another element in ammonia metabolism , 2017, World journal of gastroenterology.
[120] Samuel S. Lee,et al. Cirrhotic cardiomyopathy: Implications for liver transplantation , 2017, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[121] A. Saraya,et al. Carvedilol versus propranolol effect on hepatic venous pressure gradient at 1 month in patients with index variceal bleed: RCT , 2017, Hepatology International.
[122] A. Webster,et al. Probiotics for people with hepatic encephalopathy. , 2017, The Cochrane database of systematic reviews.
[123] R. Moreau,et al. Acute-on-chronic liver failure: an update , 2017, Gut.
[124] J. Bosch,et al. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases , 2017, Hepatology.
[125] A. Hassaneen,et al. Rifaximin and midodrine improve clinical outcome in refractory ascites including renal function, weight loss, and short-term survival , 2016, European journal of gastroenterology & hepatology.
[126] R. Formica. Simultaneous liver kidney transplantation , 2016, Current opinion in nephrology and hypertension.
[127] Richard Moreau,et al. Systemic inflammation in decompensated cirrhosis: Characterization and role in acute‐on‐chronic liver failure , 2016, Hepatology.
[128] T. Sawas,et al. Early TIPS versus endoscopic therapy for secondary prophylaxis after management of acute esophageal variceal bleeding in cirrhotic patients: a meta‐analysis of randomized controlled trials , 2016, Journal of gastroenterology and hepatology.
[129] J. Shao,et al. Population-representative Incidence of Acute-On-Chronic Liver Failure , 2016, Journal of clinical gastroenterology.
[130] G. Han,et al. Management of hepatocellular carcinoma: an overview of major findings from meta-analyses , 2016, Oncotarget.
[131] A. Frigo,et al. Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study , 2016, Hepatology.
[132] J. Bajaj. Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis , 2016, Alimentary pharmacology & therapeutics.
[133] Ezio Fornasiere,et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial , 2015, Hepatology.
[134] Min Zheng,et al. Acute‐on‐chronic liver failure precipitated by hepatic injury is distinct from that precipitated by extrahepatic insults , 2015, Hepatology.
[135] A. de Gottardi,et al. Clinical Course of acute‐on‐chronic liver failure syndrome and effects on prognosis , 2015, Hepatology.
[136] P. Tandon,et al. Risk of Bacterial Infection in Patients With Cirrhosis and Acute Variceal Hemorrhage, Based on Child-Pugh Class, and Effects of Antibiotics. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[137] E. Tapper,et al. Refining the ammonia hypothesis: a physiology-driven approach to the treatment of hepatic encephalopathy. , 2015, Mayo Clinic proceedings.
[138] A. Avenell,et al. Branched-chain amino acid supplementation in adults with cirrhosis and porto-systemic encephalopathy: systematic review. , 2014, Clinical nutrition.
[139] J. Hodson,et al. Non-selective β-blockers are associated with improved survival in patients with ascites listed for liver transplantation , 2014, Gut.
[140] C. Dai,et al. Letter: the effects of rifaximin in hepatic encephalopathy , 2014, Alimentary pharmacology & therapeutics.
[141] B. I. Kim,et al. Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhage , 2014, Hepatology.
[142] W. Saad. Portosystemic Shunt Syndrome and Endovascular Management of Hepatic Encephalopathy , 2014, Seminars in Interventional Radiology.
[143] A. Krag,et al. Systematic review with meta‐analysis: the effects of rifaximin in hepatic encephalopathy , 2014, Alimentary pharmacology & therapeutics.
[144] K. Reddy,et al. Survival in infection‐related acute‐on‐chronic liver failure is defined by extrahepatic organ failures , 2014, Hepatology.
[145] T. Roskams,et al. Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats , 2014, Hepatology.
[146] Johnny C. Hong,et al. Liver Transplantation in Highest Acuity Recipients: Identifying Factors to Avoid Futility , 2014, Annals of surgery.
[147] K. Massey,et al. Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2 , 2014, Nature Medicine.
[148] G. Han,et al. TIPS improves liver transplantation-free survival in cirrhotic patients with refractory ascites: an updated meta-analysis. , 2014, World journal of gastroenterology.
[149] P. Ciancaglini,et al. Catalytic Signature of a Heat-Stable, Chimeric Human Alkaline Phosphatase with Therapeutic Potential , 2014, PloS one.
[150] P. Tandon,et al. A MELD-based model to determine risk of mortality among patients with acute variceal bleeding. , 2014, Gastroenterology.
[151] M. Bernardi,et al. Interactions of the heart and the liver. , 2013, European heart journal.
[152] B. Sharma,et al. A Randomized, Double-Blind, Controlled Trial Comparing Rifaximin Plus Lactulose With Lactulose Alone in Treatment of Overt Hepatic Encephalopathy , 2013, The American Journal of Gastroenterology.
[153] MD Gupte,et al. The Indian perspective , 2013, BMC Proceedings.
[154] D. V. van Thiel,et al. Cirrhotic ascites review: Pathophysiology, diagnosis and management. , 2013, World journal of hepatology.
[155] P. Póvoa,et al. The Predisposition, Infection, Response and Organ Failure (Piro) Sepsis Classification System: Results of Hospital Mortality Using a Novel Concept and Methodological Approach , 2013, PloS one.
[156] M. Poca,et al. Transfusion strategies for acute upper gastrointestinal bleeding. , 2013, The New England journal of medicine.
[157] P. Kamath,et al. Acute-on chronic liver failure. , 2012, Journal of hepatology.
[158] K. Reddy,et al. Second infections independently increase mortality in hospitalized patients With cirrhosis: the north american consortium for the study of end‐stage liver disease (NACSELD) experience , 2012, Hepatology.
[159] R. Jalan,et al. Role of predisposition, injury, response and organ failure in the prognosis of patients with acute-on-chronic liver failure: a prospective cohort study , 2012, Critical Care.
[160] A. Krag,et al. Meta‐analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia , 2012, Alimentary pharmacology & therapeutics.
[161] E. Mohammadi,et al. Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.
[162] R. Mookerjee. Acute-on-chronic liver failure: the liver and portal haemodynamics , 2011, Current opinion in critical care.
[163] F. Wong,et al. Beta‐blockers in cirrhosis: Friend and foe? , 2010, Hepatology.
[164] S. Fan,et al. Liver transplantation for acute-on-chronic liver failure , 2009, Hepatology international.
[165] J. Geddes,et al. What is a randomised controlled trial? , 2009, Epidemiologia e Psichiatria Sociale.
[166] P. Angeli,et al. Combined versus sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis: results of an open randomised clinical trial , 2009, Gut.
[167] J. Henriksen,et al. Pathogenetic background for treatment of ascites and hepatorenal syndrome , 2008, Hepatology international.
[168] A. Bhalla,et al. Midodrine Versus Albumin in the Prevention of Paracentesis-Induced Circulatory Dysfunction in Cirrhotics: A Randomized Pilot Study , 2008, The American Journal of Gastroenterology.
[169] D. Thabut,et al. Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: A randomized, controlled trial , 2008, Hepatology.
[170] F. Schmidt. Meta-Analysis , 2008 .
[171] Ramon Planas,et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. , 2007, Gastroenterology.
[172] P. Boelle,et al. Erythromycin Infusion Prior to Endoscopy for Acute Upper Gastrointestinal Bleeding: A Randomized, Controlled, Double-Blind Trial , 2006, The American Journal of Gastroenterology.
[173] David M. Harris,et al. Ca2+ Influx–Induced Sarcoplasmic Reticulum Ca2+ Overload Causes Mitochondrial-Dependent Apoptosis in Ventricular Myocytes , 2005, Circulation research.
[174] A. Sanabria,et al. Randomized controlled trial. , 2005, World journal of surgery.
[175] G. Mancia,et al. Cardiac, Neuroadrenergic, and Portal Hemodynamic Effects of Prolonged Aldosterone Blockade in Postviral Child A Cirrhosis , 2005, The American Journal of Gastroenterology.
[176] E. Peña,et al. Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding , 2004, Hepatology.
[177] A. Burroughs,et al. Targeting portal pressure measurements: A critical reappraisal , 2004, Hepatology.
[178] S. Yachha,et al. Management of portal hypertension , 2002, Indian journal of pediatrics.
[179] 賢二 鈴木. 慢性副鼻腔炎に対するrandomized controlled study , 2002 .
[180] P. Hayes,et al. The role of the transjugular intrahepatic portosystemic stent shunt (TIPSS) in the management of bleeding gastric varices: clinical and haemodynamic correlations , 2002, Gut.
[181] J. Boadas,et al. Somatostatin treatment and risk stratification by continuous portal pressure monitoring during acute variceal bleeding. , 2001, Gastroenterology.
[182] P. Hsu,et al. The effects of endoscopic variceal ligation and propranolol on portal hypertensive gastropathy: a prospective, controlled trial. , 2001, Gastrointestinal endoscopy.
[183] J. Rodés,et al. Prognostic value of early measurements of portal pressure in acute variceal bleeding. , 1999, Gastroenterology.
[184] C. Sabin,et al. Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage , 1998, Hepatology.
[185] K. Foeken,et al. Overt hepatic encephalopathy precipitated by zinc deficiency. , 1991, Gastroenterology.
[186] J. Benhamou,et al. PROPRANOLOL—A MEDICAL TREATMENT FOR PORTAL HYPERTENSION? , 1980, The Lancet.
[187] J. Cohn,et al. Impaired Left Ventricular Function in Alcoholic Cirrhosis With Ascites: Ineffectiveness of Ouabain , 1974, Circulation.
[188] Bruno,et al. A Randomized Controlled , Double-Blind Trial Evaluating the Effect of Opioid-Free Versus Opioid General Anaesthesia on Postoperative Pain and Discomfort Measured by the QoR-40 , 2018 .
[189] Hsin-Chieh Yeh,et al. Effect of the 2011 vs 2003 duty hour regulation-compliant models on sleep duration, trainee education, and continuity of patient care among internal medicine house staff: a randomized trial. , 2013, JAMA internal medicine.
[190] B. Haller,et al. How to diagnose hepatic encephalopathy in the emergency department. , 2013, Annals of hepatology.
[191] U. Lüthi. ["It takes two to tango"]. , 2012, Krankenpflege. Soins infirmiers.
[192] S. Sungkanuparph,et al. A CASE SERIES AND REVIEW OF THE LITERATURE , 2011 .
[193] B. Kollen,et al. A Double-blind Randomized Controlled Trial , 2011 .
[194] V. Preedy,et al. Prospective Cohort Study , 2010 .
[195] Brian E. Keck. A Critical Reappraisal , 2010 .
[196] F. Wong. Cirrhotic cardiomyopathy , 2009, Hepatology international.
[197] G. D’Amico,et al. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. , 2006, Journal of hepatology.
[198] Consensus Document , 2005 .
[199] H. Volk,et al. Immunomodulatory therapies in sepsis , 2000, Intensive Care Medicine.
[200] V. Arroyo,et al. Compensated cirrhosis: Natural history and prognostic factors , 1987, Hepatology.
[201] K. Johnson. An Update. , 1984, Journal of food protection.
[202] E. Glaser. The randomized clinical trial. , 1972, The New England journal of medicine.